A Model to Explain the PH-dependent Specificity of Cathepsin B-catalysed Hydrolyses
Overview
Affiliations
1. Three synthetic substrates of cathepsin B (EC 3.4.22.1) with various amino acid residues at the P2 position (Cbz-Phe-Arg-NH-Mec, Cbz-Arg-Arg-NH-Mec and Cbz-Cit-Arg-NH-Mec, where Cbz represents benzyloxycarbonyl and NH-Mec represents 4-methylcoumarin-7-ylamide) were used to investigate the pH-dependency of cathepsin B-catalysed hydrolyses and to obtain information on the nature of enzyme-substrate interactions. 2. Non-linear-regression analysis of pH-activity profiles for these substrates indicates that at least four ionizable groups on cathepsin B with pKa values of 3.3, 4.55, 5.46 and greater than 7.3 can affect the rate of substrate hydrolysis. 3. Ionization of the residue with a pKa of 5.46 has a strong effect on activity towards the substrate with an arginine in P2 (8.4-fold increase in activity) but has only a moderate effect on the rate of hydrolysis with Cbz-Cit-Arg-NH-Mec (2.3-fold increase in activity) and virtually no effect with Cbz-Phe-Arg-NH-Mec. The kinetic data are consistent with this group being an acid residue with a side chain able to interact with the side chains of an arginine or a citrulline in the P2 position of a substrate. Amino acid sequence alignment and model building with the related enzyme papain (EC 3.4.22.2) suggest that Glu-245 of cathepsin B is a likely candidate. The relative importance of electrostatic and hydrophobic interactions in the S2 subsite of cathepsin B is discussed. 4. For all three substrates, activity appears after ionization of a group with a pKa of 3.3, believed to be the active-site Cys-29 of cathepsin B. The identity of the groups with pKa values of 4.55 and greater than 7.3 remains unknown.
Autophagy-lysosomal pathway impairment and cathepsin dysregulation in Alzheimer's disease.
Mancano A, Pina J, Froes B, Sciani J Front Mol Biosci. 2024; 11:1490275.
PMID: 39544403 PMC: 11560772. DOI: 10.3389/fmolb.2024.1490275.
Bibliometric Analysis of Cathepsin B Research From 2011 to 2021.
Yang X, Yin H, Zhang D, Peng L, Li K, Cui F Front Med (Lausanne). 2022; 9:898455.
PMID: 35872750 PMC: 9301081. DOI: 10.3389/fmed.2022.898455.
Hernandez M, Marone M, Gorse K, Lafrenaye A ASN Neuro. 2022; 14:17590914221099112.
PMID: 35503242 PMC: 9069603. DOI: 10.1177/17590914221099112.
Voisin A, Monville C, Plancheron A, Bere E, Gaillard A, Leveziel N Oxid Med Cell Longev. 2019; 2019:5637075.
PMID: 31885803 PMC: 6925809. DOI: 10.1155/2019/5637075.
Poreba M, Groborz K, Vizovisek M, Maruggi M, Turk D, Turk B Chem Sci. 2019; 10(36):8461-8477.
PMID: 31803426 PMC: 6839509. DOI: 10.1039/c9sc00997c.